- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03610282
EEG Study of IV Methylphenidate-Induced Emergence From Propofol Sedation
February 19, 2020 updated by: Ken Solt, Massachusetts General Hospital
Electroencephalogram Study of Intravenous Methylphenidate-Induced Emergence From Propofol Sedation
The investigators are performing this research study to find out if intravenous (IV) methylphenidate (commonly known as Ritalin) can help people recover faster from propofol sedation.
The investigators also want to know how IV methylphenidate acts in the brain and whether IV methylphenidate is safe to take with an anesthetic (a drug or agent used to decrease or eliminate the feeling of pain by causing unconsciousness) without causing too many side effects.
The brain's electrical activity will be studied and recorded using a machine called an electroencephalogram (EEG).
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
During this research study, participants will receive propofol, and propofol and IV methylphenidate together, at a high enough dose to achieve unconsciousness (make study participants "fall asleep").
During one visit participants will receive propofol and a saline placebo; during another visit participants will be given both propofol and IV methylphenidate together.
The investigators will record EEG the entire time, The investigators will also ask some questions related to cognitive function.
Study Type
Interventional
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Between the ages of 18 to 45
- Normal body weight and habitus, BMI ≤ 30
- Non-smoker
- No history of taking stimulants
- American Society of Anesthesiologists (ASA) physical status classification P1
Exclusion Criteria:
• Chronic health conditions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EEG Dynamics
EEG data will be collected on patients receiving propofol and IV methylphenidate together.
|
Subjects will receive a bolus of IV methylphenidate during propofol infusion at one of the study visits.
Other Names:
Subjects will received propofol for up to 100 minutes.
|
Placebo Comparator: Propofol EEG Dynamics
EEG data will be collected on patients receiving propofol and a saline placebo.
|
Subjects will received propofol for up to 100 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in multitaper spectral estimates of EEG power during a continuous infusion of propofol.
Time Frame: Up to 100 minutes
|
Change from baseline in multitaper spectral estimates of EEG power associated with the administration of IV methylphenidate.
|
Up to 100 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ken Solt, MD, Massachusetts General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2019
Primary Completion (Anticipated)
November 1, 2020
Study Completion (Anticipated)
November 1, 2021
Study Registration Dates
First Submitted
July 26, 2018
First Submitted That Met QC Criteria
July 26, 2018
First Posted (Actual)
August 1, 2018
Study Record Updates
Last Update Posted (Actual)
February 21, 2020
Last Update Submitted That Met QC Criteria
February 19, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Hypnotics and Sedatives
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Propofol
- Methylphenidate
Other Study ID Numbers
- 2018P001421
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anesthesia
-
Samsun UniversityCompletedAnesthesia | Regional Anesthesia | Anesthesia ManagementTurkey
-
Charite University, Berlin, GermanyCompletedAnesthesia, Local | Anesthesia | Anesthesia; Adverse EffectGermany
-
Novocol Pharmaceutical of Canada, Inc.CompletedAnesthesia, Local | Dental Anesthesia | Anesthesia, ReversalUnited States
-
Aligarh Muslim UniversityCompletedAnesthesia | Anesthesia Intubation Complication | Anesthesia; Adverse EffectIndia
-
Universitas Sebelas MaretIndonesia Endowment Fund for EducationNot yet recruitingAnesthesia | Anesthesia; Reaction
-
University of PecsCompleted
-
Hormozgan University of Medical SciencesUnknownAnesthesia | Anesthesia; FunctionalIran, Islamic Republic of
-
University of ChicagoRecruitingAnesthesia | Patient Satisfaction | Anesthesia Risks | Anesthesia Consent | Consent RetentionUnited States
-
Assistance Publique - Hôpitaux de ParisINSERM UMR-942, Paris, France; M3DISIMNot yet recruitingPrediction Models for Cardiovascular and Neurocognitive Disease Risk in the General Population (CME)Anesthesia, Local | AnesthesiaFrance
-
Matthew BorzageRecruitingAnesthesia | Anesthesia; ReactionUnited States
Clinical Trials on IV Methylphenidate
-
National Institute on Alcohol Abuse and Alcoholism...CompletedNormal PhysiologyUnited States
-
University of ArkansasCompleted
-
Mahidol UniversityNot yet recruiting
-
Massachusetts General HospitalFood and Drug Administration (FDA); Center for Psychiatry And Behavioral Medicine...Completed
-
Florida International UniversityNational Institute of Mental Health (NIMH)CompletedAttention Deficit Disorder With HyperactivityUnited States
-
Ironshore Pharmaceuticals and Development, IncCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Boston Children's HospitalNational Institute of Mental Health (NIMH)CompletedEpilepsy | Attention Deficit Disorder With HyperactivityUnited States
-
Massachusetts General HospitalMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Completed
-
Massachusetts General HospitalMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Completed
-
Milton S. Hershey Medical CenterChildren's Miracle NetworkTerminatedBehavioral Insomnia of Childhood | Attention Deficit Disorder With HyperactivityUnited States